Orient Technologies (NSE: ORIENTTECH) Q3 FY26 results: Why short-term margin pain may be the price of securing long-cycle government and services revenue
Read More 6 minute read Pharma Industry News Can Partner Therapeutics’ zenocutuzumab-zbco deliver a first-line breakthrough in NRG1+ lung cancer? Zenocutuzumab-zbco by Partner Therapeutics shows durable first-line response in NRG1+ NSCLC. Find out what the new eNRGy trial data means for patients. bySrinathDecember 7, 2025